- Open Access
NADPH oxidase mediates β-amyloid peptide-induced activation of ERK in hippocampal organotypic cultures
© Serrano et al; licensee BioMed Central Ltd. 2009
Received: 22 July 2009
Accepted: 5 October 2009
Published: 5 October 2009
Previous studies have shown that beta amyloid (Aβ) peptide triggers the activation of several signal transduction cascades in the hippocampus, including the extracellular signal-regulated kinase (ERK) cascade. In this study we sought to characterize the cellular localization of phosphorylated, active ERK in organotypic hippocampal cultures after acute exposure to either Aβ (1-42) or nicotine.
We observed that Aβ and nicotine increased the levels of active ERK in distinct cellular localizations. We also examined whether phospho-ERK was regulated by redox signaling mechanisms and found that increases in active ERK induced by Aβ and nicotine were blocked by inhibitors of NADPH oxidase.
Our findings indicate that NADPH oxidase-dependent redox signaling is required for Aβ-induced activation of ERK, and suggest a similar mechanism may occur during early stages of Alzheimer's disease.
Beta amyloid (Aβ) peptide is typically considered neurotoxic as it is present in high levels and accumulates in plaques in the brain of Alzheimer's disease (AD) patients . However, Aβ also is present in the normal brain at lower levels than in the disease state, suggesting that it has normal cellular and physiological functions . Therefore, studies of the impact of exposure of the brain to Aβ could provide important information with respect to its role during both physiological and pathophysiological processes. It has been demonstrated that acute treatment of organotypic hippocampal cultures with nanomolar concentrations of oligomeric Aβ (1-42) leads to the activation of extracellular signal-regulated kinase (ERK) via the alpha 7 nicotinic acetylcholine receptor (α 7nAChR) [3, 4]. This signaling cascade involves an increase in calcium and activation of ERK mediated by phosphoinositide-3 kinase (PI3K), which is followed by increases in CREB phosphorylation [3–6]. Similar to Aβ, nicotine treatment causes ERK activation via α 7nAChR and requires PI3K. However, protein kinase A (PKA) appears to be an upstream regulator of ERK activation after nicotine treatment, but not after Aβ treatment . The activation of different signaling cascades by Aβ and nicotine suggest the possibility of differential cellular activation and/or localization by these molecules. In this study we sought to characterize the cellular localization of the Aβ- and nicotine-induced increases in active ERK in area CA1 of hippocampal organotypic cultures.
Reactive oxygen species (ROS) typically are characterized as molecules involved in neurotoxicity and neurodegeneration . However, substantial evidence suggests that ROS also function as small messenger molecules that are normal components of signal transduction cascades required for physiological processes such as synaptic plasticity, learning, and memory . Because it is known that Aβ peptides can produce ROS, it is important to identify the source of the ROS production, as well as downstream effectors of ROS. NADPH oxidase is particularly intriguing as a possible source of ROS produced by Aβ peptides. NADPH oxidase is a tightly regulated, multiprotein enzyme that produces large quantities of the ROS superoxide that has been well characterized in phagocytic cells . The active oxidase is made up of several protein components, including two membrane proteins, gp91 phox and p22 phox (also known as cytochrome b558), and three cytosolic proteins, p47 phox , p67 phox , and the small GTP-binding protein Rac. Upon stimulation, the cytosolic proteins translocate to the membrane to form a complex with cytochrome b558, which results in enzymatic activation and production of superoxide [10, 11]. In recent years, NADPH oxidase and NADPH oxidase-like enzymes (NOX) have been described in non-phagocytic cells [12, 13]. For example, NADPH oxidase has been observed in peripheral neurons [14, 15], cerebral cortical neurons [16, 17], and cerebellar Purkinje neurons  among others. NADPH oxidase also is present in the hippocampus, including pyramidal neurons in area CA1 [19, 20]. Superoxide produced by NADPH oxidase predominately has been studied with respect to neurotoxicity [15, 21], but there also is evidence that superoxide is required for hippocampal long-term potentiation and hippocampus-dependent memory [22–25]. Therefore, NADPH oxidase could play an important role not only in disease conditions, but also during normal neuronal function. Interestingly, it has been demonstrated that in brains of AD patients there is an increase in the expression of NADPH oxidase proteins  and that AD model mice lacking gp91 phox do not develop oxidative stress, cerebrovascular dysfunction, or behavioral deficits . Furthermore, in vitro studies using cortical neurons have demonstrated an involvement of NADPH oxidase in response to Aβ (1-42) stimulation . These observations suggest that NADPH oxidase could contribute to the oxidative stress associated with AD, and also implicate it in regulating signal transduction cascades under more physiological conditions. In this study we sought to investigate whether Aβ peptide regulates the ERK signaling cascade via NADPH oxidase in hippocampal organotypic cultures.
Differential cellular expression of ERK after Aβ- and nicotine-treatments
Aβ peptide-induced activation of ERK is blocked by the NADPH oxidase inhibitors apocynin and DPI
Nicotine-induced activation of ERK is blocked by the NADPH oxidase inhibitors apocynin and DPI
Contribution of α7nAChR to the Aβ- and nicotine-induced activation of ERK
Acute treatments of organotypic hippocampal cultures with either Aβ or nicotine have been found to increase ERK phosphorylation [3, 4]. Herein, we have expanded on those previous observations by using immunocytochemistry and have determined that the increase in ERK phosphorylation after Aβ treatment was localized to the cell soma and dendrites of hippocampal CA1 neurons (Figure 1). Interestingly, our data indicate that nicotine treatment induced ERK phosphorylation only in the dendritic compartment because the cell soma lacked enhanced phospho-ERK immunoreactivity. The differences in the localization of phospho-ERK activation following Aβ and nicotine suggest that ERK activation is mediated by different upstream signaling modules. Consistent with this observation, it has been shown that both Aβ and nicotine trigger the activation of ERK, but by using distinct intermediate kinases . More studies are necessary to specifically address the implications of this differential compartmentalization of ERK phosphorylation after these two treatments.
Importantly, we also observed that acute treatment with nanomolar concentrations of Aβ induced the activation of ERK in neurons, but not glial cells (Figure 1), as we did not observe dual staining for phospho-ERK with markers for either astrocytes or microglia. Similarly, nicotine treatment showed no evidence of active ERK immunoreactivity in glia cells (Figure 1). It previously was observed that Aβ treatment can cause increases in active ERK in glia cells; however, these increases in active ERK were after chronic exposure to Aβ, suggesting that the cells were responding to neurotoxic events [33–35]. In addition, chronic treatment with nanomolar concentrations of either monomeric or oligomeric Aβ, as well as higher concentrations (micromolar) of fibrillar Aβ, are typically associated with ERK activation leading to neurotoxicity [3, 36]. Furthermore, it has been demonstrated that in early stages of AD there is a transient increase in active ERK in astrocytes that might represent a response to axonal damage and presynaptic loss . All together, these findings suggest a scenario where low concentrations of Aβ induces the physiological activation of ERK in neurons, whereas higher concentrations of Aβ induces the pathophysiological activation of ERK in glial cells.
Earlier studies demonstrated that treatment of acute hippocampal slices with a superoxide-generating system causes ERK phosphorylation . The involvement of ERK signaling in synaptic plasticity and memory function has been studied intensely  and several studies have demonstrated an important role for NADPH oxidase and ROS in synaptic plasticity and learning and memory [22, 40]. Moreover, N-methyl-D-aspartate (NMDA) receptor-dependent activation of ERK in the hippocampus is mediated by NADPH oxidase . Our findings strongly suggest that both Aβ and nicotine treatments trigger an increase in ERK phosphorylation in hippocampal pyramidal neurons via NADPH oxidase (Figure 2) and are in agreement with a previous study in cortical neurons . There also is evidence that neutrophils stimulated with Aβ fragments (25-35) at micromolar concentrations activate ERK, resulting in the activation of NADPH oxidase to produce superoxide . This apparent difference in signaling modules could be due to the cell type, Aβ peptide solution, or the Aβ concentration and time of incubation used. Regardless, there is extensive evidence that superoxide produced by NADPH oxidase triggers ERK activation during both physiological and pathophysiological conditions [42–44]. An involvement of NADPH oxidase in ERK-mediated signaling after nicotine treatment has not been studied extensively. However, it was shown that in non-neuronal cells nicotine can modulate cell function via both NADPH oxidase and ERK . Taken together, our results are in agreement with others and point to a significant role for NADPH oxidase in ERK activation by either Aβ or nicotine.
In agreement with previous studies  we found that nanomolar concentrations of MLA inhibited the increase in active ERK after Aβ treatment (Figure 4). The importance of the interaction of Aβ with α7nAChRs during both normal synaptic plasticity and pathologic conditions such as AD is well recognized , but further studies are necessary to increase our understanding of the signaling cascades mediating these processes.
At the present time the subcellular localization of NADPH oxidase involved in the Aβ/ERK signaling pathway in the hippocampus is not clear. Our findings indicate that Aβ treatment causes the activation of ERK in pyramidal neuron cell bodies and dendrites and we have previously shown a synaptic localization of NADPH oxidase in the hippocampus . One possible scenario is that Aβ causes the activation of NADPH oxidase postsynaptically and that the production of ROS causes the activation of ERK in both cell bodies and dendritic compartments. Another possibility is that NADPH oxidase is present presynaptically and that after Aβ treatment, the superoxide that is produced travels trans-synaptically, leading to the activation of ERK in postsynaptic pyramidal neurons. These possibilities remain to be examined.
Whether the involvement of the α7nChR in the Aβ-induced ERK activation is upstream of the NADPH oxidase activation is still unclear. α7nChRs have been shown to be present in both presynaptic and postsynaptic compartments of pyramidal neurons, as well as in GABAergic interneurons [47–49]. It has been suggested that nAChRs at presynaptic locations on excitatory neurons could impact hippocampal synaptic plasticity . Thus, if the nicotinic receptor activation is indeed upstream to NADPH oxidase activation, one can speculate that Aβ binds to presynaptic nAChRs, enhancing release of glutamate, which would lead to increases in postsynaptic calcium followed by activation of NADPH oxidase and ERK. Another possibility is that Aβ binds to nicotinic receptors in the postsynaptic neuron causing depolarization, NADPH oxidase activation, and subsequent ERK activation. More studies will be necessary to directly investigate which additional mechanisms are involved in the Aβ-induced ERK activation.
Our findings indicate that NADPH oxidase-dependent redox signaling is required for Aβ-induced activation of ERK in hippocampal neurons. These observations expand our understanding of the regulation and signaling cascades activated by Aβ and provide insight about the signaling cascades that might be triggered during the early stages of Alzheimer's disease.
Hippocampal slice cultures and treatment
Slice cultures were prepared from P7 Sprague-Dawley rat pups and maintained in culture according to the method of Stoppini et. al. . On the seventh day of culture, hippocampal slices were treated in the presence or absence of the NADPH inhibitors apocynin (100 μM, Sigma/Aldrich, St. Louis, MO) for 30 min, or diphenyleneiodomium (DPI 10 μM, Calbiochem, San Diego, CA) for 1 hr and the α7nAChR inhibitor methyllycaconitine (MLA 10 nM, Tocris, Ellisville, MO) for 30 min. Media was removed and replaced with media containing the inhibitors in the presence or absence of Aβ1-42 (100 nM; Calbiochem, San Diego, CA), or nicotine (500 nM; Sigma/Aldrich, St. Louis, MO) for 5 or 10 min, respectively.
Aβ preparation: Stock solution of synthetic rat Aβ1-42 (Calbiochem, San Diego, CA) was prepared at 100 mM in 200 mM HEPES, pH 8.0. The solution was gently agitated for ~ 30 min, aliquoted, and stored at -80°C. As previously published this method of Aβ preparation forms oligomers and not high molecular weight or fibrillar aggregate forms .
After treatment with media in the presence or absence of the inhibitors and either Aβ (100 nM, 5 min) or nicotine (500 nM, 10 min) hippocampal slice cultures were fixed in 4% paraformaldehyde and 4% sucrose overnight at 4°C. Then the cultures were washed in phosphate buffer solution (PBS), permeabilized with 0.1% Triton X-100 and blocked with 4% normal goat serum for 30 min each. Slice cultures were incubated in phospho-ERK1/2 ([1:1000], Cell Signaling Technology Inc., Danvers, MA), NeuN (neuron-specific nuclear protein, [1:100], Millipore/Chemicon, Billerica, MA), MAP2 (microtubulin associated protein, [1:1000], Cell Signaling Technology Inc., Danvers, MA), GFAP (glial fibrillary acidic protein, [1:100], (Invitrogen/Molecular Probes, Carlsbad, CA), isolectin GS-IB4 (IB4, [1:1000], Invitrogen/Molecular Probes, Carlsbad, CA), and glutamic acid decarboxylase (GAD67, Millipore/Chemicon, Billerica, MA) overnight, rinsed with PBS and incubated for 2 hr with secondary antibodies Alexa 488 [1:200], and Alexa 594, [1:200], Invitrogen/Molecular Probes, Carlsbad, CA). Slices were washed in PBS, mounted on coverslips and analyzed using a Zeiss LSM 510 meta confocal microscope.
Western blot hybridization
Hippocampal slices were homogenized in 10 mM HEPES, 1 mM EGTA, 1 mM EDTA, 150 mM NaCl, 50 mM NaF, and 10 mM Na4P2O7 supplemented with protease inhibitors, and phosphatase inhibitors (PI-I, PI-II, Sigma). The homogenate was sonicated and equivalent amounts of protein from each sample were resolved via 10% SDS-PAGE, transferred to Immobilon membranes, and incubated in I-Block (Applied Biosystems/Tropix, Foster City, CA). Blots then were incubated with primary antibodies phospho-ERK2 (1:3000), or ERK1/2 (1:3000) for 1 hr followed by horseradish peroxidase-linked secondary antibody and developed using enhanced chemiluminescence (Millipore/Amersham, Billerica, MA). Densitometric analyses of immunoreactivity were conducted using NIH image software.
Statistical analyses were performed using a one-way ANOVA with Tukey's test for multiple comparisons to determine significant differences between control and treatment groups (control versus Aβ or nicotine; Aβ versus Aβ + drug; nicotine versus nicotine + drug). A p value of less than 0.05 was considered statistically significant. For Western blots analyses the results described represent at least n = 3 and each experimental condition contained replicates of between 6 - 8 slices.
Supported by NIH grants NS034007 (EK), NS047384 (EK), DK079638 (RGP), and an Alzheimer's Association Investigator-Initiated Research Grant (EK).
- Kuo YM, Emmerling MR, Vigo-Pelfrey C, Kasunic TC, Kirkpatrick JB, Murdoch GH, Ball MJ, Roher AE: Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains. J Biol Chem. 1996, 271: 4077-4081. 10.1074/jbc.271.8.4077.View ArticlePubMedGoogle Scholar
- Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, Iwatsubo T, Sisodia S, Malinow R: APP processing and synaptic function. Neuron. 2003, 37: 925-937. 10.1016/S0896-6273(03)00124-7.View ArticlePubMedGoogle Scholar
- Bell KA, O'Riordan KJ, Sweatt JD, Dineley KT: MAPK recruitment by beta-amyloid in organotypic hippocampal slice cultures depends on physical state and exposure time. J Neurochem. 2004, 91: 349-361. 10.1111/j.1471-4159.2004.02722.x.View ArticlePubMedGoogle Scholar
- Dineley KT, Westerman M, Bui D, Bell K, Ashe KH, Sweatt JD: Beta-amyloid activates the mitogen-activated protein kinase cascade via hippocampal alpha7 nicotinic acetylcholine receptors: In vitro and in vivo mechanisms related to Alzheimer's disease. J Neurosci. 2001, 21: 4125-4133.PubMedGoogle Scholar
- Dineley KT, Bell KA, Bui D, Sweatt JD: beta-Amyloid peptide activates alpha 7 nicotinic acetylcholine receptors expressed in Xenopus oocytes. J Biol Chem. 2002, 277: 25056-25061. 10.1074/jbc.M200066200.View ArticlePubMedGoogle Scholar
- Dougherty JJ, Wu J, Nichols RA: Beta-amyloid regulation of presynaptic nicotinic receptors in rat hippocampus and neocortex. J Neurosci. 2003, 23: 6740-6747.PubMedGoogle Scholar
- Halliwell B: Oxidative stress and neurodegeneration: where are we now?. J Neurochem. 2006, 97: 1634-1658. 10.1111/j.1471-4159.2006.03907.x.View ArticlePubMedGoogle Scholar
- Kishida KT, Klann E: Sources and targets of reactive oxygen species in synaptic plasticity and memory. Antioxid Redox Signal. 2007, 9: 233-244. 10.1089/ars.2007.9.233.PubMed CentralView ArticlePubMedGoogle Scholar
- Bedard K, Krause KH: The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev. 2007, 87: 245-313. 10.1152/physrev.00044.2005.View ArticlePubMedGoogle Scholar
- Heyworth PG, Curnutte JT, Nauseef WM, Volpp BD, Pearson DW, Rosen H, Clark RA: Neutrophil nicotinamide adenine dinucleotide phosphate oxidase assembly. Translocation of p47-phox and p67-phox requires interaction between p47-phox and cytochrome b558. J Clin Invest. 1991, 87: 352-356. 10.1172/JCI114993.PubMed CentralView ArticlePubMedGoogle Scholar
- Park JW, Ma M, Ruedi JM, Smith RM, Babior BM: The cytosolic components of the respiratory burst oxidase exist as a M(r) approximately 240,000 complex that acquires a membrane-binding site during activation of the oxidase in a cell-free system. J Biol Chem. 1992, 267: 17327-17332.PubMedGoogle Scholar
- Bokoch GM, Knaus UG: NADPH oxidases: not just for leukocytes anymore!. Trends Biochem Sci. 2003, 28: 502-508. 10.1016/S0968-0004(03)00194-4.View ArticlePubMedGoogle Scholar
- Lambeth JD: NOX enzymes and the biology of reactive oxygen. Nat Rev Immunol. 2004, 4: 181-189. 10.1038/nri1312.View ArticlePubMedGoogle Scholar
- Dvorakova M, Hohler B, Richter E, Burritt JB, Kummer W: Rat sensory neurons contain cytochrome b558 large subunit immunoreactivity. Neuroreport. 1999, 10: 2615-2617. 10.1097/00001756-199908200-00032.View ArticlePubMedGoogle Scholar
- Tammariello SP, Quinn MT, Estus S: NADPH oxidase contributes directly to oxidative stress and apoptosis in nerve growth factor-deprived sympathetic neurons. J Neurosci. 2000, 20: RC53-PubMedGoogle Scholar
- Kim YH, Koh JY: The role of NADPH oxidase and neuronal nitric oxide synthase in zinc-induced poly(ADP-ribose) polymerase activation and cell death in cortical culture. Exp Neurol. 2002, 177: 407-418. 10.1006/exnr.2002.7990.View ArticlePubMedGoogle Scholar
- Noh KM, Koh JY: Induction and activation by zinc of NADPH oxidase in cultured cortical neurons and astrocytes. J Neurosci. 2000, 20: RC111-PubMedGoogle Scholar
- Mizuki K, Kadomatsu K, Hata K, Ito T, Fan QW, Kage Y, Fukumaki Y, Sakaki Y, Takeshige K, Sumimoto H: Functional modules and expression of mouse p40(phox) and p67(phox), SH3- domain-containing proteins involved in the phagocyte NADPH oxidase complex. Eur J Biochem. 1998, 251: 573-582. 10.1046/j.1432-1327.1998.2510573.x.View ArticlePubMedGoogle Scholar
- Serrano F, Kolluri NS, Wientjes FB, Card JP, Klann E: NADPH oxidase immunoreactivity in the mouse brain. Brain Res. 2003, 988: 193-198. 10.1016/S0006-8993(03)03364-X.View ArticlePubMedGoogle Scholar
- Tejada-Simon MV, Serrano F, Villasana LE, Kanterewicz BI, Wu GY, Quinn MT, Klann E: Synaptic localization of a functional NADPH oxidase in the mouse hippocampus. Mol Cell Neurosci. 2005, 29: 97-106. 10.1016/j.mcn.2005.01.007.PubMed CentralView ArticlePubMedGoogle Scholar
- Wu DC, Teismann P, Tieu K, Vila M, Jackson-Lewis V, Ischiropoulos H, Przedborski S: NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Proc Natl Acad Sci USA. 2003, 100: 6145-6150. 10.1073/pnas.0937239100.PubMed CentralView ArticlePubMedGoogle Scholar
- Kishida KT, Hoeffer CA, Hu D, Pao M, Holland SM, Klann E: Synaptic plasticity deficits and mild memory impairments in mouse models of chronic granulomatous disease. Mol Cell Biol. 2006, 26: 5908-5920. 10.1128/MCB.00269-06.PubMed CentralView ArticlePubMedGoogle Scholar
- Klann E: Cell-permeable scavengers of superoxide prevent long-term potentiation in hippocampal area CA1. J Neurophysiol. 1998, 80: 452-457.PubMedGoogle Scholar
- Klann E, Roberson ED, Knapp LT, Sweatt JD: A role for superoxide in protein kinase C activation and induction of long-term potentiation. J Biol Chem. 1998, 273: 4516-4522. 10.1074/jbc.273.8.4516.View ArticlePubMedGoogle Scholar
- Thiels E, Urban NN, Gonzalez-Burgos GR, Kanterewicz BI, Barrionuevo G, Chu CT, Oury TD, Klann E: Impairment of long-term potentiation and associative memory in mice that overexpress extracellular superoxide dismutase. J Neurosci. 2000, 20: 7631-7639.PubMedGoogle Scholar
- Shimohama S, Tanino H, Kawakami N, Okamura N, Kodama H, Yamaguchi T, Hayakawa T, Nunomura A, Chiba S, Perry G, et al: Activation of NADPH oxidase in Alzheimer's disease brains. Biochem Biophys Res Commun. 2000, 273: 5-9. 10.1006/bbrc.2000.2897.View ArticlePubMedGoogle Scholar
- Park L, Zhou P, Pitstick R, Capone C, Anrather J, Norris EH, Younkin L, Younkin S, Carlson G, McEwen BS, Iadecola C: Nox2-derived radicals contribute to neurovascular and behavioral dysfunction in mice overexpressing the amyloid precursor protein. Proc Natl Acad Sci USA. 2008, 105: 1347-1352. 10.1073/pnas.0711568105.PubMed CentralView ArticlePubMedGoogle Scholar
- Shelat PB, Chalimoniuk M, Wang JH, Strosznajder JB, Lee JC, Sun AY, Simonyi A, Sun GY: Amyloid beta peptide and NMDA induce ROS from NADPH oxidase and AA release from cytosolic phospholipase A2 in cortical neurons. J Neurochem. 2008, 106: 45-55. 10.1111/j.1471-4159.2008.05347.x.View ArticlePubMedGoogle Scholar
- Wang HY, Lee DH, D'Andrea MR, Peterson PA, Shank RP, Reitz AB: beta-Amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology. J Biol Chem. 2000, 275: 5626-5632. 10.1074/jbc.275.8.5626.View ArticlePubMedGoogle Scholar
- Wang HY, Lee DH, Davis CB, Shank RP: Amyloid peptide Abeta(1-42) binds selectively and with picomolar affinity to alpha7 nicotinic acetylcholine receptors. J Neurochem. 2000, 75: 1155-1161. 10.1046/j.1471-4159.2000.0751155.x.View ArticlePubMedGoogle Scholar
- Alkondon M, Albuquerque EX: Diversity of nicotinic acetylcholine receptors in rat hippocampal neurons. I. Pharmacological and functional evidence for distinct structural subtypes. J Pharmacol Exp Ther. 1993, 265: 1455-1473.PubMedGoogle Scholar
- Alkondon M, Pereira EF, Wonnacott S, Albuquerque EX: Blockade of nicotinic currents in hippocampal neurons defines methyllycaconitine as a potent and specific receptor antagonist. Mol Pharmacol. 1992, 41: 802-808.PubMedGoogle Scholar
- Abramov AY, Duchen MR: The role of an astrocytic NADPH oxidase in the neurotoxicity of amyloid beta peptides. Philos Trans R Soc Lond B Biol Sci. 2005, 360: 2309-2314. 10.1098/rstb.2005.1766.PubMed CentralView ArticlePubMedGoogle Scholar
- Qin L, Liu Y, Cooper C, Liu B, Wilson B, Hong JS: Microglia enhance beta-amyloid peptide-induced toxicity in cortical and mesencephalic neurons by producing reactive oxygen species. J Neurochem. 2002, 83: 973-983. 10.1046/j.1471-4159.2002.01210.x.View ArticlePubMedGoogle Scholar
- Wilkinson BL, Landreth GE: The microglial NADPH oxidase complex as a source of oxidative stress in Alzheimer's disease. J Neuroinflammation. 2006, 3: 30-10.1186/1742-2094-3-30.PubMed CentralView ArticlePubMedGoogle Scholar
- Chong YH, Shin YJ, Lee EO, Kayed R, Glabe CG, Tenner AJ: ERK1/2 activation mediates Abeta oligomer-induced neurotoxicity via caspase-3 activation and tau cleavage in rat organotypic hippocampal slice cultures. J Biol Chem. 2006, 281: 20315-20325. 10.1074/jbc.M601016200.View ArticlePubMedGoogle Scholar
- Webster B, Hansen L, Adame A, Crews L, Torrance M, Thal L, Masliah E: Astroglial activation of extracellular-regulated kinase in early stages of Alzheimer disease. J Neuropathol Exp Neurol. 2006, 65: 142-151. 10.1097/01.jnen.0000199599.63204.6f.View ArticlePubMedGoogle Scholar
- Kanterewicz BI, Knapp LT, Klann E: Stimulation of p42 and p44 mitogen-activated protein kinases by reactive oxygen species and nitric oxide in hippocampus. J Neurochem. 1998, 70: 1009-1016.View ArticlePubMedGoogle Scholar
- Sweatt JD: Mitogen-activated protein kinases in synaptic plasticity and memory. Curr Opin Neurobiol. 2004, 14: 311-317. 10.1016/j.conb.2004.04.001.View ArticlePubMedGoogle Scholar
- Kishida KT, Pao M, Holland SM, Klann E: NADPH oxidase is required for NMDA receptor-dependent activation of ERK in hippocampal area CA1. J Neurochem. 2005, 94: 299-306. 10.1111/j.1471-4159.2005.03189.x.PubMed CentralView ArticlePubMedGoogle Scholar
- Andersen JM, Myhre O, Aarnes H, Vestad TA, Fonnum F: Identification of the hydroxyl radical and other reactive oxygen species in human neutrophil granulocytes exposed to a fragment of the amyloid beta peptide. Free Radic Res. 2003, 37: 269-279. 10.1080/1071576021000046631.View ArticlePubMedGoogle Scholar
- Frank GD, Eguchi S, Yamakawa T, Tanaka S, Inagami T, Motley ED: Involvement of reactive oxygen species in the activation of tyrosine kinase and extracellular signal-regulated kinase by angiotensin II. Endocrinology. 2000, 141: 3120-3126. 10.1210/en.141.9.3120.PubMedGoogle Scholar
- Chan SH, Hsu KS, Huang CC, Wang LL, Ou CC, Chan JY: NADPH oxidase-derived superoxide anion mediates angiotensin II-induced pressor effect via activation of p38 mitogen-activated protein kinase in the rostral ventrolateral medulla. Circ Res. 2005, 97: 772-780. 10.1161/01.RES.0000185804.79157.C0.View ArticlePubMedGoogle Scholar
- Espinosa A, Leiva A, Pena M, Muller M, Debandi A, Hidalgo C, Carrasco MA, Jaimovich E: Myotube depolarization generates reactive oxygen species through NAD(P)H oxidase; ROS-elicited Ca2+ stimulates ERK, CREB, early genes. J Cell Physiol. 2006, 209: 379-388. 10.1002/jcp.20745.View ArticlePubMedGoogle Scholar
- Jaimes EA, Tian RX, Raij L: Nicotine: the link between cigarette smoking and the progression of renal injury?. Am J Physiol Heart Circ Physiol. 2007, 292: H76-82. 10.1152/ajpheart.00693.2006.View ArticlePubMedGoogle Scholar
- Dineley KT: Beta-amyloid peptide--nicotinic acetylcholine receptor interaction: the two faces of health and disease. Front Biosci. 2007, 12: 5030-5038. 10.2741/2445.View ArticlePubMedGoogle Scholar
- Alkondon M, Pereira EF, Barbosa CT, Albuquerque EX: Neuronal nicotinic acetylcholine receptor activation modulates gamma-aminobutyric acid release from CA1 neurons of rat hippocampal slices. J Pharmacol Exp Ther. 1997, 283: 1396-1411.PubMedGoogle Scholar
- Gray R, Rajan AS, Radcliffe KA, Yakehiro M, Dani JA: Hippocampal synaptic transmission enhanced by low concentrations of nicotine. Nature. 1996, 383: 713-716. 10.1038/383713a0.View ArticlePubMedGoogle Scholar
- Ji D, Lape R, Dani JA: Timing and location of nicotinic activity enhances or depresses hippocampal synaptic plasticity. Neuron. 2001, 31: 131-141. 10.1016/S0896-6273(01)00332-4.View ArticlePubMedGoogle Scholar
- Stoppini L, Buchs PA, Muller D: A simple method for organotypic cultures of nervous tissue. J Neurosci Methods. 1991, 37: 173-182. 10.1016/0165-0270(91)90128-M.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.